These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7816279)

  • 1. Painless subcutaneous erythropoietin (rHuEpo) injection--is it the panacea?
    Hörl WH
    Nephrol Dial Transplant; 1994; 9(9):1224-5. PubMed ID: 7816279
    [No Abstract]   [Full Text] [Related]  

  • 2. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help?
    Morris KP; Hughes C; Hardy SP; Matthews JN; Coulthard MG
    Nephrol Dial Transplant; 1994; 9(9):1299-301. PubMed ID: 7816294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 4. rHuEPO in the treatment of postpartum anemia: subcutaneous versus intravenous administration.
    Zimmermann R; Breymann C; Huch R; Huch A
    Clin Investig; 1994; 72(6 Suppl):S25-30. PubMed ID: 7950168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.
    Zehnder C; Blumberg A
    Nephron; 1991; 57(4):485-6. PubMed ID: 2046836
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of the efficacy of measures to reduce pain after subcutaneous administration of epoetin alfa.
    Frenken LA; van Lier HJ; Koene RA
    Nephrol Dial Transplant; 1994; 9(9):1295-8. PubMed ID: 7816293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients.
    Bommer J; Barth HP; Zeier M; Mandelbaum A; Bommer G; Ritz E; Reichel H; Novack R
    Contrib Nephrol; 1991; 88():136-43. PubMed ID: 2040175
    [No Abstract]   [Full Text] [Related]  

  • 9. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG; Fischer ER; Harris DC
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoietin can be administered during dialysis. A kinetic analysis.
    Petersen J; Kang MS; Hays MT
    ASAIO J; 1996; 42(1):27-33. PubMed ID: 8808454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous erythropoietin.
    Bommer J; Ritz E; Weinreich T; Bommer G; Ziegler T
    Lancet; 1988 Aug; 2(8607):406. PubMed ID: 2899821
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Perazella MA
    Am J Kidney Dis; 1995 Dec; 26(6):1000; author reply 1001. PubMed ID: 7503059
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
    Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
    Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration.
    Granolleras C; Branger B; Shaldon S; Nonnast-Daniel B; Koch KM; Pollok M; Baldamus CA
    Contrib Nephrol; 1991; 88():144-8; discussion 149-51. PubMed ID: 2040176
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Sadjadi SA
    Am J Kidney Dis; 1995 Dec; 26(6):1000-1. PubMed ID: 7503060
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous versus subcutaneous EPO: is the cost benefit acceptable?
    Fraticelli M; D'Amico M; Conte F
    Am J Kidney Dis; 2003 May; 41(5):1122; author reply 1122. PubMed ID: 12722048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.